Study Finds Nirmatrelvir/Ritonavir Did Not Reduce Risk For Long COVID

Healio (1/16, Feller) reports, “Paxlovid [nirmatrelvir/ritonavir] did not reduce the risk for long COVID among vaccinated, nonhospitalized people who received it within a month of their first SARS-CoV-2 infection, a study showed.” In a study published in the Journal of Medical Virology, “roughly 16% of patients treated with Paxlovid experienced long COVID compared with 14% of patients not treated with Paxlovid.”